2021-10-12| Special

Are Digital Therapeutics the Next Generation of Medical Products?

by Sahana Shankar
Share To
Technology has made huge strides in not only health monitoring and disease diagnosis but also active therapeutics. It is a fast-growing health sector that has seen investments grow by 40% year on year since 2013.

A wide range of products backed by evidence and peer-reviewed studies are now available to address cognitive disorders like ADHD, autoimmune diseases, insomnia, and psychiatric disorders like schizophrenia. As a result, there is value for consumers (improved outcomes), physicians (real-time monitoring of symptoms), and investors (large market size), which can drive digital therapeutics for more cost-effective solutions in the future.

At the Biofuture conference, a panel consisting of diverse voices based on the broad spectrum of products in the digital therapeutics space discussed the evolution of digital therapeutics, how they serve unmet clinical needs, how they can redefine therapy/medicine in the future, and how to build successful and sustainable business models for the next generation of products.

GO Prime with only $1.49 now

Cortisol: New Discoveries on its Impact Across Health, Culture, and Evolution
Why NVIDIA’s CEO Huang Said AI Fostering Life Science:Highlighting GPU’s Applications in Biotech
Revolutionary AI-Powered Respiratory Monitor Maker Gets Financial Boost with Latest Funding
Researchers Predict Drug Interactions with Machine Learning to Enhance Patient Safety
USC-Led Study Reveals Benefits of Fasting-Mimicking Diet in Reducing Disease Risk and Slowing Aging
Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro
Targeted Cancer Therapy Breakthrough: Degrader-Antibody Conjugates (DACs) Advance to Clinical Trials
Scroll to Top